Table 3.
Hazard ratios and 95 % CI of association between NSAID use and risk of total renal cell carcinoma (RCC) by age in the NIH–AARP Diet and Health Study, stratified by age-groups
| <63 years |
≥63 years |
|||
|---|---|---|---|---|
| Cases/person- years |
MV-adjusted HR (95 % CI)a |
Cases/person- years |
MV-adjusted HR (95 % CI)a |
|
| Aspirin | ||||
| None | 103/335,393 | Reference | 181/357,056 | Reference |
| Any | 329/929,131 | 1.05 (0.84–1.32) | 471/961,305 | 0.86 (0.72–1.03) |
| Frequency of any use | ||||
| Monthly | 130/444,791 | 0.88 (0.68–1.14) | 174/373,506 | 0.86 (0.70–1.06) |
| Weekly | 76/223,900 | 1.00 (0.75–1.35) | 99/212,958 | 0.84 (0.66–1.07) |
| Daily | 123/260,440 | 1.29 (0.99–1.69) | 198/374,840 | 0.89 (0.73–1.10) |
| Nonaspirin NSAIDs | ||||
| None | 152/477,198 | Reference | 325/638,128 | Reference |
| Any | 280/787,326 | 1.16 (0.95–1.41) | 327/680,232 | 0.95 (0.81–1.11) |
| Frequency | ||||
| Monthly | 154/470,547 | 1.08 (0.86–1.35) | 188/388,415 | 0.95 (0.80–1.14) |
| Weekly | 76/194,725 | 1.28 (0.97–1.69) | 79/151,939 | 1.04 (0.81–1.33) |
| Daily | 50/122,054 | 1.25 (0.90–1.73) | 60/139,879 | 0.83 (0.63–1.10) |
| Type and combination of NSAIDs | ||||
| Neither | 35/145,237 | Reference | 113/197,832 | Reference |
| Aspirin only | 117/331,961 | 1.38 (0.95–2.02) | 212/440,296 | 0.77 (0.61–0.97) |
| Frequency | ||||
| Monthly | 42/156,052 | 1.16 (0.74–1.82) | 85/167,550 | 0.91 (0.69–1.21) |
| Weekly | 27/74,351 | 1.48 (0.90–2.46) | 40/89,321 | 0.75 (0.52–1.08) |
| Daily | 48/101,558 | 1.59 (1.03–2.47) | 87/183,425 | 0.68 (0.51–0.90) |
| Nonaspirin NSAIDs only | 68/190,156 | 1.63 (1.08–2.45) | 68/159,224 | 0.79 (0.58–1.07) |
| Frequency | ||||
| Monthly | 30/95,365 | 1.48 (0.91–2.42) | 28/72,196 | 0.73 (0.48–1.10) |
| Weekly | 17/48,324 | 1.64 (0.92–2.94) | 17/34,176 | 0.94 (0.57–1.57) |
| Daily | 21/46,467 | 1.89 (1.09–3.25) | 23/52,852 | 0.78 (0.50–1.22) |
| Both aspirin and nonaspirin NSAIDs | 212/597,170 | 1.43 (0.99–2.04) | 259/521,009 | 0.79 (0.64–0.99) |
| Frequency | ||||
| Both monthly | 65/211,167 | 1.36 (0.90–2.05) | 70/147,435 | 0.83 (0.62–1.12) |
| Aspirin monthly plus nonaspirin NSAIDs weekly or daily |
23/77,572 | 1.29 (0.76–2.19) | 19/58,521 | 0.57 (0.35–0.93) |
| Nonaspirin monthly plus aspirin weekly or daily |
59/164,015 | 1.34 (0.88–2.05) | 90/168,784 | 0.80 (0.60–1.05) |
| Both weekly or daily | 65/144,416 | 1.67 (1.10–2.52) | 80/146,269 | 0.84 (0.63–1.12) |
*
All p’s for interaction >0.05
a
The models were adjusted for the same covariates as the multivariate model in Table 2